1. In situ sprayed NIR-responsive, analgesic black phosphorus-based gel for diabetic ulcer treatment.
- Author
-
Ouyang J, Ji X, Zhang X, Feng C, Tang Z, Kong N, Xie A, Wang J, Sui X, Deng L, Liu Y, Kim JS, Cao Y, and Tao W
- Subjects
- Anesthetics, Local administration & dosage, Animals, Cell Line, Cell Proliferation drug effects, Diabetes Mellitus, Experimental, Drug Evaluation, Preclinical, Endothelial Cells drug effects, Fibrinogen administration & dosage, Gels, Human Umbilical Vein Endothelial Cells, Humans, Lidocaine administration & dosage, Male, Mice, Inbred BALB C, Neovascularization, Physiologic drug effects, Thrombin administration & dosage, Diabetic Foot therapy, Phosphorus administration & dosage, Photothermal Therapy, Smart Materials administration & dosage, Wound Healing drug effects
- Abstract
The treatment of diabetic ulcer (DU) remains a major clinical challenge due to the complex wound-healing milieu that features chronic wounds, impaired angiogenesis, persistent pain, bacterial infection, and exacerbated inflammation. A strategy that effectively targets all these issues has proven elusive. Herein, we use a smart black phosphorus (BP)-based gel with the characteristics of rapid formation and near-infrared light (NIR) responsiveness to address these problems. The in situ sprayed BP-based gel could act as 1) a temporary, biomimetic "skin" to temporarily shield the tissue from the external environment and accelerate chronic wound healing by promoting the proliferation of endothelial cells, vascularization, and angiogenesis and 2) a drug "reservoir" to store therapeutic BP and pain-relieving lidocaine hydrochloride (Lid). Within several minutes of NIR laser irradiation, the BP-based gel generates local heat to accelerate microcirculatory blood flow, mediate the release of loaded Lid for "on-demand" pain relief, eliminate bacteria, and reduce inflammation. Therefore, our study not only introduces a concept of in situ sprayed, NIR-responsive pain relief gel targeting the challenging wound-healing milieu in diabetes but also provides a proof-of-concept application of BP-based materials in DU treatment., Competing Interests: The authors declare no competing interest.
- Published
- 2020
- Full Text
- View/download PDF